{
    "nctId": "NCT06214598",
    "briefTitle": "Anti-Inflammatory Diet in BRC Patients on Aromatase Inhibitors",
    "officialTitle": "Anti-Inflammatory Dietary Intervention in Breast Cancer Patients Receiving Aromatase Inhibitors",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 90,
    "primaryOutcomeMeasure": "Nutritional status",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Age: 45 to 70 years\n* Postmenopausal women\n* Histologically confirmed BRC, stage I to IIIa\n* ER positive /HER2 negative\n* Application of adjuvant hormone therapy with aromase inhibitors: 6 to 30 months\n* Body mass index from 20 to 34.9 kg/m 2\n* Able to understand the requirements of the study and provide written information consent\n\nExclusion Criteria:\n\n* Metastatic or locally advanced disease\n* HER2-positive tumors\n* Presence of other malignant or serious chronic diseases\n* Active infections\n* Previous stroke or heart attack,\n* Rheumatoid arthritis and other types of autoimmune diseases\n* Presence of a significant neurological deficit\n* Dementia\n* Allergy to the ingredients of the dietary preparation or to fish, fish oil and nuts fruits.\n* Allergies to evening primrose oil or other oils containing gamma-linolenic acid (borage, black currant)\n* Use of lipid-lowering drugs (statins, Normolip)\n* Current use of warfarin or other anticoagulants\n* Corticosteroid therapy for the last month\n* Use of dietary supplements based on fish oil, evening primrose, and flaxseed oils, omega 3-6-9 fatty acids, multivitamins with added omega-3 of fatty acids 3 months before the start of the study",
    "sex": "FEMALE",
    "minimumAge": "45 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}